Research programme: camptothecin-somatostatin conjugate - Biomeasure/IpsenAlternative Names: BIM-23A807
Latest Information Update: 20 Sep 2011
At a glance
- Originator Ipsen Inc
- Mechanism of Action Somatostatin receptor 2 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Small cell lung cancer